Corvus Pharmaceuticals Inc

NASDAQ:CRVSUnited States

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.

Contact Information

Headquarters

863 Mitten Rd Ste 102BURLINGAME, CA, United States 94010-1311

Phone

650-900-4520

Fax

302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer

Richard Miller

Chief Financial Officer

Leiv Lea

Senior Vice President, Chief Business Officer

Jeffrey Arcara

Senior Vice President - Pharmaceutical Development

William Jones

Independent Director

Ian Clark